Improving the treatment of Epstein-Barr virus infectious mononucleosis in children


  • S.O. Кramarov Bogomolets National Medical University, Kyiv, Ukraine
  • V.O. Shadrin Bogomolets National Medical University, Kyiv, Ukraine
  • V.V. Yevtushenko Bogomolets National Medical University, Kyiv, Ukraine
  • I.V. Shpak Bogomolets National Medical University, Kyiv, Ukraine
  • L.A. Bolshakova Kyiv Children’s Clinical Infectious Diseases Hospital, Kyiv, Ukraine
  • Т.M. Kaminskaya Kyiv Children’s Clinical Infectious Diseases Hospital, Kyiv, Ukraine



children, infectious mononucleosis, Epstein-Barr infection, liver, ursodeoxycholic acid


Background. In Ukraine, as in the whole world, there is a tendency to increase in the number of diffuse liver diseases. Increased percentage of patients with liver disease among adults is mostly determined by the damages to hepatobiliary system in childhood. The purpose of the study was to evaluate the effectiveness of ursodeoxycholic acid (UDCA) in the therapy of liver damages due to Epstein-Barr virus (EBV). Materials and methods. Research design: prospective, open-label, controlled. Sixty children with EBV infectious mononucleosis (IM) aged 1 to 18 years old were screened. All patients were observed, examined during the acute period of the disease, and divided into 2 groups. The children of the main group (n = 35) received standard therapy for EBV IM in combination with UDCA, patients of the control group (n = 25) received standard treatment alone. Results. Received data showed that therapy improved by means of UDCA in EBV IM and liver damage promotes a faster regression of the main symptoms of infection, such as fever, appetite loss and jaundice, already on day 7 from the beginning of treatment and a more rapid norma­lization of indicators of the functional state of the liver (alanine aminotransferase, bilirubin, alkaline phosphatase, gamma glutamyltransferase, lactate dehydrogenase). The drug was well tolerated, no adverse reactions were observed. Conclusions. The inclusion of UDCA in the treatment scheme can improve the effectiveness of advanced therapy compared with standard one, promotes a more rapid regression of infection symptoms and a more rapid norma­lization of indicators of the functional state of the liver.


Kramarev SA, Litvinenko NG, Palatnaia LA. Epstein-Barr virus infection in children. Sovremennaya pediatriya.2004;(34):13-18. (in Russian).

Denisova MF. Scientific and practical priorities of pediatric hepatology. Modern Gastroenterology.2009;(50):115-119. (in Russian).

Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002 Mar;35(3):635-8. doi: 10.1053/jhep.2002.31782.

Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ. 2003 Jan;10 Suppl 1:S48-58. doi: 10.1038/sj.cdd.4401119.

Görbig MN, Ginès P, Bataller R, et al. Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. J Hepatol. 2001 Feb;34(2):222-9.

Feldmann G. Liver apoptosis. J Hepatol. 1997;26 Suppl 2:1-11.

Faulkner GC, Krajewski AS, Crawford DH. The ins and outs of EBV infеction. Trends in Microbiology. 2000;8(4):185-189. doi: 10.1016/S0966-842X(00)01742-X. 

Kramarev SА, Vigovskaya ОV. Chronic forms of Epstein-Barr viral infection in children. Modern approaches to diagnostics and treatment. Sovremennaya pediatriya.2008;(19):103-108. (in Russian).

Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998 Nov;4(6):469-76.

Maeda A, Wakiguchi H, Yokoyama W, Hisakawa H, Tomoda T, Kurashige T. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. J Infect Dis. 1999 Apr;179(4):1012-5. doi: 10.1086/314691.

Volkova GI. Epshteina-Barr virusnyi gepatit u detei. Diss. kand. med. nauk [Epstein-Barr virus hepatitis in children. PhD diss.]. Moscow; 2013. 20 p. (in Russian).

Aprosina ZG, Ignatova TM, Kozlovskaia LV, authors; Serov BB, Aprosina ZG, editors. Khronicheskii virusnyi gepatit [Chronic viral hepatitis]. Moscow: Meditsina; 2002. 384 p. (in Russian).

Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000 Dec;32(6):1403-8. doi: 10.1053/jhep.2000.20243.

Janeczko J. Immunomodulatory treatment of lymphopenia after infectious mononucleosis. Przegl Epidemiol. 2001;55(4):433-41. (in Polish).

Urazova OI, Pomogaeva AP, Novitsky VV, Potarskaya EV, Shevtsova NM. Subpopulation composition and metabolism of mononuclear lymphocytes in children with infectious mononucleosis. Infectious Diseases. 2004;2(4):17-21. (in Russian).

Gubergrits NB, Lukashevich GM, Fomenko PG, Beliaeva NV. Zhelchnyi refliuks: sovremennye teoriia i praktika [Gall-reflux: modern theory and practice]. Moscow; 2014. 36 p. (in Russian).

Kikuchi K, Miyakawa H, Abe K, et al. Vanishing bile duct syndrome associated with chronic EBV infection. Dig Dis Sci. 2000 Jan;45(1):160-5.



Original Researches